Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Nets $3.8M in SBIR/STTR Grants

NEW YORK (GenomeWeb News) – Asuragen has won $3.8 million in new stimulus funding from the National Institutes of Health, which it will use to advance its molecular diagnostics programs for cancer and genetic diseases, the company said today.

The company said that it received the funding through the Small Business Innovation Research and Small Business Technology Transfer programs, and the American Recovery and Reinvestment Act.

Asuragen will use the Phase I and Phase II funding to study microRNA and RNA biomarkers and to develop diagnostic tests for cancer, including non-small cell lung cancer, pancreatic cancer, cervical cancer, and melanoma. It also intends to expand its multiplex diagnostic panels for testing of mutations in leukemia and other malignancies, and to develop amplification technologies to enable diagnostic microarrays and reliable high-throughput detection of Fragile X and related syndromes.

"The NIH grant mechanism allows us to push the technological envelope and develop products with ideal workflow that are readily adopted in the clinical laboratory," Asuragen CEO and CSO Matt Winkler said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.